1 April 2026 in Clinical oncohematology
BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.
6 July 2026 in Blood Immunology & Cellular Therapy
1 July 2025 in Clinical oncohematology
BACKGROUND. In recent years, the number of allogeneic hematopoietic stem cell transplantations (allo-HSCT) has continued to rise due to the ongoing improvement of transplantation technologies and rapid growth of bone marrow donor registries. Clinical outcomes of allo-HSCT depend on many factors including ethnic matching of patients and donors. There is evidence on a higher efficacy of allo-HSCT from the national registry donors compared with the donors from international registries. AIM. To assess the efficacy of allo-HSCT from the Russian and foreign donors. MATERIALS & METHODS. This retrospective clinical study enrolled 585 patients with various hematologic diseases. In the RM Gorbacheva Research Institute, in the period from 2010 to 2019, all patients received allo-HSCT from 9/10 or 10/10 HLA-matched unrelated donors from the Russian (n = 141) and international (n = 444) registries. In the early post-transplant period, cyclophosphamide was administered to all patients to prevent the graft-versus-host disease (GVHD). Paired analysis was carried out in two groups of patients formed and balanced according to the following criteria: age, disease variant, conditioning regimen intensity, graft source, the number of allo-HSCT recipients out of remission, and the year of transplantation. The median follow-up in the total group was 17 months (range 1–74 months). RESULTS. The outcomes of allo-HSCT from the Russian and international donors appeared to be compatible: the 5-year overall survival was 64 % and 62 %, respectively (p = 0.19), the 5-year event-free survival was 57 % and 43 % (p = 0.14), the transplant mortality was 17 % and 18 % (p = 0.62), and the cumulative relapse incidence was 12 % and 20 %, respectively (p = 0.08). The paired analysis yielded similar results in both groups for all the above mentioned end points. The risks of acute as well as chronic GVHD appeared to be the same. CONCLUSION. The long-terms outcomes of allo-HSCT from the Russian and foreign donors proved to be compatible. Further development of the Federal Bone Marrow Donor Registry will provide availability and affordability of allo-HSCT for more citizens of the Russian Federation. This remains an issue of current concern because of the challenges of logistics, financing, and a longer interval between the donor search through international registries and allo-HSCT performance.
19 March 2025 in Oncohematology
Background. FMS‑like tyrosine kinase 3 (FLT3) gene mutations are the most frequently detected genetic aberrations in adult patients with newly diagnosed acute myeloid leukemia (AML), identified in approximately 30 % of patients. The addition of midostaurin, an FLT3 tyrosine kinase inhibitor, to standard therapy and after allogeneic hematopoietic stem cell transplantation (allo‑HSCT) improves overall (OS) and event‑free survival (EFS). Aim. To evaluate the effect of adding midostaurin to standard therapy in adult patients with FLT3‑mutated AML. To evaluate the impact of allo‑HSCT performed in first complete remission on the survival of patients treated in combination with midostaurin. Materials and methods. The study enrolled 276 patients with newly diagnosed AML with FLT3 mutation. 153 of them received combination therapy with midostaurin, 123 – first‑line therapy without FLT3 inhibitors. In the combination therapy group allo‑HSCT in first complete remission was performed in 35 (22.9 %) patients. Results. The response rate was higher in the combination therapy group and was 84 % versus 66 % in the control group (p 0.01). with a median follow‑up of 19 (2–130) months, the median OS was not achieved in both groups. The 18‑month OS was 60 % (95 % confidence interval (CI) 50–69) in the midostaurin group and 53 % (95 % CI 43–61) without it (p = 0.12). Median EFS was 11.6 months (95 % CI 9.1–13.8) and 6.7 months (95 % CI 4.2–10.2) respectively (p = 0.046). The 18‑month EFS was 33 % (95 % CI 24–42) and 31 % (95 % CI 23–40). In multivariate analysis, factors associated with worse EFS were older age and FLT3 internal tandem duplication. Age, leukocytosis at the time of diagnosis, and the presence of unfavorable cytogenetic abnormalities had a negative effect on EFS. Midostaurin therapy was associated with EFS improvement. In a landmark analysis with a 6‑month time point, OS was 89 % (95 % CI 69–96) in the allo‑HSCT group versus 38 % without it (95 % CI 20–55) (p = 0.002). EFS was 75 % (95 % CI 50–88) and 13 % (95 % CI 5–26), respectively (p 0.001). Conclusion. The addition of midostaurin to standard treatment contributes to an increased response rate and improved survival in patients with FLT3‑mutated AML. Allo‑HSCT in first complete remission remains the preferred option for remission consolidation in patients treated with tyrosine kinase inhibitors.